Publication

Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry

Boonstra, P. A., Steeghs, N., Farag, S., van Coevorden, F., Gelderblom, H., Grunhagen, D. J., Desar, I. M. E., van der Graaf, W. T. A., Bonenkamp, J. J., Reyners, A. K. L. & van Etten, B., Mar-2019, In : EJSO. 45, 3, p. 410-415 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Boonstra, P. A., Steeghs, N., Farag, S., van Coevorden, F., Gelderblom, H., Grunhagen, D. J., ... van Etten, B. (2019). Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry. EJSO, 45(3), 410-415. https://doi.org/10.1016/j.ejso.2018.09.013

Author

Boonstra, P. A. ; Steeghs, N. ; Farag, S. ; van Coevorden, F. ; Gelderblom, H. ; Grunhagen, D. J. ; Desar, I. M. E. ; van der Graaf, W. T. A. ; Bonenkamp, J. J. ; Reyners, A. K. L. ; van Etten, B. / Surgical and medical management of small bowel gastrointestinal stromal tumors : A report of the Dutch GIST registry. In: EJSO. 2019 ; Vol. 45, No. 3. pp. 410-415.

Harvard

Boonstra, PA, Steeghs, N, Farag, S, van Coevorden, F, Gelderblom, H, Grunhagen, DJ, Desar, IME, van der Graaf, WTA, Bonenkamp, JJ, Reyners, AKL & van Etten, B 2019, 'Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry', EJSO, vol. 45, no. 3, pp. 410-415. https://doi.org/10.1016/j.ejso.2018.09.013

Standard

Surgical and medical management of small bowel gastrointestinal stromal tumors : A report of the Dutch GIST registry. / Boonstra, P. A.; Steeghs, N.; Farag, S.; van Coevorden, F.; Gelderblom, H.; Grunhagen, D. J.; Desar, I. M. E.; van der Graaf, W. T. A.; Bonenkamp, J. J.; Reyners, A. K. L.; van Etten, B.

In: EJSO, Vol. 45, No. 3, 03.2019, p. 410-415.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Boonstra PA, Steeghs N, Farag S, van Coevorden F, Gelderblom H, Grunhagen DJ et al. Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry. EJSO. 2019 Mar;45(3):410-415. https://doi.org/10.1016/j.ejso.2018.09.013


BibTeX

@article{674c7e3832e64b9e9e7817db4f1cf1de,
title = "Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry",
abstract = "Background: A cohort of 201 patients with small bowel gastrointestinal stromal tumors (GIST) treated between January 1st, 2009 and December 31st, 2016 in five GIST expertise centers in the Netherlands was analyzed. Goal of this study was to describe the clinical, surgical and pathological characteristics of this rare subpopulation of GIST patients, registered in the Dutch GIST registry.Methods: Clinical outcomes and risk factors of patients with small bowel GIST who underwent surgery or treated with systemic therapy were analyzed. A classification was made based on disease status at diagnosis (localized vs. metastasized).Results: 201 patients with small bowel GIST were registered of which 138 patients (69{\%}) were diagnosed with localized disease and 63 patients (31{\%}) with metastatic disease. Approximately 19{\%} of the patients had emergency surgery, and in 22{\%} GIST was an accidental finding. In patients with high risk localized disease, recurrence occurred less often in patients who received adjuvant treatment (4/32) compared to patients who did not (20/31, p <0.01). Disease progression during palliative imatinib treatment occurred in 23 patients (28{\%}) after a median of 20.7 (range 1.8-47.1) months. Ongoing response was established in 52/82 patients on first line palliative treatment with imatinib after a median treatment time of 30.6 (range 2.5-155.3) months.Conclusion: Patients with small-bowel GIST more frequently present with metastatic disease when compared to patients with gastric GIST in literature. We advocate for Prospective registration of these patients and investigate the use of surgery in patients with limited metastatic disease. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.",
keywords = "GIST, Small bowel, Surgery, Treatment, Sarcoma, PHASE-II TRIAL, IMATINIB MESYLATE, DOSE IMATINIB, MULTICENTER, PATHOLOGY, EFFICACY, SAFETY",
author = "Boonstra, {P. A.} and N. Steeghs and S. Farag and {van Coevorden}, F. and H. Gelderblom and Grunhagen, {D. J.} and Desar, {I. M. E.} and {van der Graaf}, {W. T. A.} and Bonenkamp, {J. J.} and Reyners, {A. K. L.} and {van Etten}, B.",
year = "2019",
month = "3",
doi = "10.1016/j.ejso.2018.09.013",
language = "English",
volume = "45",
pages = "410--415",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "ELSEVIER SCI LTD",
number = "3",

}

RIS

TY - JOUR

T1 - Surgical and medical management of small bowel gastrointestinal stromal tumors

T2 - A report of the Dutch GIST registry

AU - Boonstra, P. A.

AU - Steeghs, N.

AU - Farag, S.

AU - van Coevorden, F.

AU - Gelderblom, H.

AU - Grunhagen, D. J.

AU - Desar, I. M. E.

AU - van der Graaf, W. T. A.

AU - Bonenkamp, J. J.

AU - Reyners, A. K. L.

AU - van Etten, B.

PY - 2019/3

Y1 - 2019/3

N2 - Background: A cohort of 201 patients with small bowel gastrointestinal stromal tumors (GIST) treated between January 1st, 2009 and December 31st, 2016 in five GIST expertise centers in the Netherlands was analyzed. Goal of this study was to describe the clinical, surgical and pathological characteristics of this rare subpopulation of GIST patients, registered in the Dutch GIST registry.Methods: Clinical outcomes and risk factors of patients with small bowel GIST who underwent surgery or treated with systemic therapy were analyzed. A classification was made based on disease status at diagnosis (localized vs. metastasized).Results: 201 patients with small bowel GIST were registered of which 138 patients (69%) were diagnosed with localized disease and 63 patients (31%) with metastatic disease. Approximately 19% of the patients had emergency surgery, and in 22% GIST was an accidental finding. In patients with high risk localized disease, recurrence occurred less often in patients who received adjuvant treatment (4/32) compared to patients who did not (20/31, p <0.01). Disease progression during palliative imatinib treatment occurred in 23 patients (28%) after a median of 20.7 (range 1.8-47.1) months. Ongoing response was established in 52/82 patients on first line palliative treatment with imatinib after a median treatment time of 30.6 (range 2.5-155.3) months.Conclusion: Patients with small-bowel GIST more frequently present with metastatic disease when compared to patients with gastric GIST in literature. We advocate for Prospective registration of these patients and investigate the use of surgery in patients with limited metastatic disease. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

AB - Background: A cohort of 201 patients with small bowel gastrointestinal stromal tumors (GIST) treated between January 1st, 2009 and December 31st, 2016 in five GIST expertise centers in the Netherlands was analyzed. Goal of this study was to describe the clinical, surgical and pathological characteristics of this rare subpopulation of GIST patients, registered in the Dutch GIST registry.Methods: Clinical outcomes and risk factors of patients with small bowel GIST who underwent surgery or treated with systemic therapy were analyzed. A classification was made based on disease status at diagnosis (localized vs. metastasized).Results: 201 patients with small bowel GIST were registered of which 138 patients (69%) were diagnosed with localized disease and 63 patients (31%) with metastatic disease. Approximately 19% of the patients had emergency surgery, and in 22% GIST was an accidental finding. In patients with high risk localized disease, recurrence occurred less often in patients who received adjuvant treatment (4/32) compared to patients who did not (20/31, p <0.01). Disease progression during palliative imatinib treatment occurred in 23 patients (28%) after a median of 20.7 (range 1.8-47.1) months. Ongoing response was established in 52/82 patients on first line palliative treatment with imatinib after a median treatment time of 30.6 (range 2.5-155.3) months.Conclusion: Patients with small-bowel GIST more frequently present with metastatic disease when compared to patients with gastric GIST in literature. We advocate for Prospective registration of these patients and investigate the use of surgery in patients with limited metastatic disease. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

KW - GIST

KW - Small bowel

KW - Surgery

KW - Treatment

KW - Sarcoma

KW - PHASE-II TRIAL

KW - IMATINIB MESYLATE

KW - DOSE IMATINIB

KW - MULTICENTER

KW - PATHOLOGY

KW - EFFICACY

KW - SAFETY

U2 - 10.1016/j.ejso.2018.09.013

DO - 10.1016/j.ejso.2018.09.013

M3 - Article

VL - 45

SP - 410

EP - 415

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 3

ER -

ID: 92450166